<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097847</url>
  </required_header>
  <id_info>
    <org_study_id>OPEN (29BRC17.0115)</org_study_id>
    <nct_id>NCT04097847</nct_id>
  </id_info>
  <brief_title>Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study</brief_title>
  <acronym>OPEN</acronym>
  <official_title>Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      osteoradionecrosis (ORN) affects up to 30% of irradiated patients and can occur up to several
      decades after stopping treatment. Differents therapeutics exist but there is no consensus
      concerning the management of the maxillary ORN. The understanding of new pathological
      mechanisms opens the way to new therapeutic perspectives.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evolution of the osteoradionecrosis lesion after introducing PENTOCLO protocol</measure>
    <time_frame>2 years</time_frame>
    <description>Retrospective study based on recovering patient data from medical records</description>
  </primary_outcome>
  <enrollment type="Actual">96</enrollment>
  <condition>Osteoradionecrosis of Jaw</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline-Tocopherol-Clodronate</intervention_name>
    <description>the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.</description>
    <other_name>Pentoclo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients treated at Brest hospital University for ENT cancer and who had cervicofacial
        radiotherapy, with maxillary and / or mandibular osteoradionecrosis treated with PENTOCLO
        alone or in combination with other therapies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 being or having been treated by pentoclo combination for an
             osteoradionecrosis of the jaw

        Exclusion Criteria:

          -  Tumoral recidivism

          -  Precocious stop of pentoclo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoradionecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clodronic Acid</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

